EQS-Adhoc: Vitruvia Medical AG: Annual results as of 31.12.2022 and outlook 2023
EQS-Ad-hoc: Vitruvia Medical AG / Key word(s): Annual Results/Annual Report
Vitruvia Medical AG: Annual results as of 31.12.2022 and outlook 2023
25-Jun-2023 / 09:59 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Vitruvia Medical AG: Annual results as of 31.12.2022 and outlook 2023
Anglikon, June 25, 2023: Vitruvia Medical AG reported net income after taxes of CHF -1,095,349.38 for the year ended December 31, 2022, compared to CHF -8,002,497.53 in the previous year.
On a consolidated basis, Vitruvia Medical AG generated revenues of EUR 1,525,529.-- and operating earnings before interest, taxes, depreciation and amortization (EBITA) of EUR -912,086. Earnings after taxes amount to EUR -1,484,556 compared to the previous year of EUR -8,131,520.00.
Outlook 2023
For the current year, Vitruvia Medical AG and its subsidiary LT technologies GmbH & Co. KG to generate revenues of approximately EUR 1.8 million and earnings (before interest, taxes, depreciation and amortization) of approximately EUR 304,000 (unconsolidated).
On a consolidated basis, Vitruvia Medical AG expects a further improvement in earnings compared to the previous year, which will, however, still be in negative territory.
About Vitruvia Medical AG:
Vitruvia Medical AG is a Swiss investment company focused on the repair, production and trade of medical devices as well as surgical instruments.
Vitruvia thus combines innovative and sustainable solutions for medical-technical progress, customer benefit and economic success.
Vitruvia Medical AG
Markus A. Bertschin
President of the Board of Directors
Kesselackerstrasse 18
CH-5611 Anglikon
[email protected]
End of Inside Information
25-Jun-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com
|
Language: |
English |
Company: |
Vitruvia Medical AG |
|
Kesselackerstr. 18 |
|
5611 Anglikon |
|
Switzerland |
Phone: |
+41 44 915 33 78 |
E-mail: |
[email protected] |
Internet: |
www.vitruvia-med.com |
ISIN: |
CH0461931419 |
WKN: |
A2PDWF |
Listed: |
Regulated Unofficial Market in Munich |
EQS News ID: |
1664849 |
|
End of Announcement |
EQS News Service |
1664849 25-Jun-2023 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
Umsatzerlöse1 |
0,00 |
0,00 |
0,00 |
5,60 |
1,97 |
1,42 |
1,75 |
EBITDA1,2 |
0,00 |
0,00 |
0,00 |
-0,96 |
-0,75 |
-0,91 |
0,06 |
EBITDA-Marge3 |
0,00 |
0,00 |
0,00 |
-17,14 |
-38,07 |
-64,08 |
|
EBIT1,4 |
0,00 |
0,00 |
0,00 |
-1,31 |
-7,69 |
-1,24 |
-0,37 |
EBIT-Marge5 |
0,00 |
0,00 |
0,00 |
-23,39 |
-390,36 |
-87,32 |
-21,14 |
Jahresüberschuss1 |
0,00 |
0,00 |
0,00 |
-1,54 |
-7,71 |
-1,48 |
-0,54 |
Netto-Marge6 |
0,00 |
0,00 |
0,00 |
-27,50 |
-391,37 |
-104,23 |
-30,86 |
Cashflow1,7 |
0,00 |
0,00 |
0,00 |
-0,21 |
-0,78 |
-0,67 |
-0,10 |
Ergebnis je Aktie8 |
0,00 |
0,00 |
0,00 |
-0,85 |
-4,19 |
-0,59 |
-0,21 |
Dividende8 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: BDO
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Vitruvia Medical |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
A2PDWF |
1,600 |
|
4,02 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
0,00 |
0,00 |
0,00 |
-0,64 |
KBV |
KCV |
KUV |
EV/EBITDA |
-8,04 |
- |
2,30 |
86,16 |
Dividende '22 in € |
Dividende '23 in € |
Div.-Rendite '23 in % |
Hauptversammlung |
0,00 |
0,00 |
0,00 |
24.06.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
|
30.09.2024 |
|
01.05.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
76,60% |
188,81% |
60,00% |
300,00% |
|
|